Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia
Arteriosclerosis, Thrombosis, and Vascular Biology · 2024-06 · 44 (6) · 1447-1454
DOI: 10.1161/atvbaha.123.320609 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024-06. Verfasst von Sophie Béliard und 7 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille University, APHM, INSERM, INRAE, C2VN, Marseille, France (S.B., R.V.). Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Cholesterol, LDL, Homozygote, Angiopoietin-Like Protein 3. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Patients with homozygous familial hypercholesterolemia (HoFH) remain at very high cardiovascular risk despite the best standard of care lipid-lowering treatment. The addition of evinacumab, an angiopoietin-like protein 3 monoclonal antibody, more than halves low-density lipoprotein cholesterol in short-term studies. This study evaluated whether the evinacumab response was durable in the long term and improved cardiovascular outcome. METHODS: The OLE ELIPSE HoFH (Open-Label Extension to Evinacumab Lipid Studies in Patients With HoFH) study included newly diagnosed patients and those completing the ELIPSE HoFH trial, on stable lipid-lowering therapy including lipoprotein apheresis but not lomitapide. All patients received evinacumab (15 mg/kg intravenously) every 4 weeks, with no change in concomitant lipid-lowering treatment during the first 6 months. The primary efficacy end points were the mean absolute and percentage changes in low-density lipoprotein cholesterol from baseline to 6 months. A key secondary end point was cardiovascular event–free survival, which was compared with a control HoFH cohort not treated with evinacumab or lomitapide and matched for age, sex, and lipoprotein apheresis, derived from French Registry of Familial hypercholesterolemia. RESULTS: Twelve patients, 5 women and 7 men (12–57 years), were enrolled in 3 centers in France. At 6 months, the mean low-density lipoprotein cholesterol reduction with evinacumab was 3.7 mmol/L or 56% (from 6.5 mmol/L at baseline to 2.8 mmol/L; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aix Marseille University, APHM, INSERM, INRAE, C2VN, Marseille, France (S.B., R.V.).
- APHM, Department of Nutrition, Metabolic Diseases, Endocrinology, La Conception Hospital, Marseille, France (S.B., R.V.).
- Sorbonne Université, Lipidology and Cardiovascular Prevention Unit, Hémobiothérapie Unit, APHP, Hôpital Pitié-Salpètriêre, Paris (S.S.).
- Université de Bourgogne, Pediatric Intensive Care and Monitoring Unit, CHU Dijon, France (S.L.-R.).
- Department of Public Health Expertise, Paris, France (A.V.).
- Centre ELLA Santé, Paris, France (E.B.).
ORCID-Profile: Sophie Béliard, Samir Saheb, Alexandre Vimont, René Valero, Éric Bruckert, Michel Farnier, Antonio Gallo
Zitieren
APA
Béliard, S., Saheb, S., Litzler-Renault, S., Vimont, A., Valero, R., Bruckert, É., Farnier, M., & Gallo, A. (2024). Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 44(6), 1447-1454. https://doi.org/10.1161/atvbaha.123.320609
Vancouver
Béliard S, Saheb S, Litzler-Renault S, Vimont A, Valero R, Bruckert É, et al. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;44(6):1447-1454. doi:10.1161/atvbaha.123.320609
BibTeX
@article{Bliard2024,
author = {Béliard, Sophie and Saheb, Samir and Litzler-Renault, Stéphanie and Vimont, Alexandre and Valero, René and Bruckert, Éric and Farnier, Michel and Gallo, Antonio},
title = {Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2024},
volume = {44},
number = {6},
pages = {1447--1454},
doi = {10.1161/atvbaha.123.320609}
}
EUVIMED